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Abstract
Background: Active surveillance after neoadjuvant thera-
pies has emerged among several malignancies. During ac-
tive surveillance, frequent assessments are performed to 
detect residual disease and surgery is only reserved for 
those patients in whom residual disease is proven or highly 
suspected without distant metastases. After neoadjuvant 
chemoradiotherapy (nCRT), nearly one-third of esophageal 
cancer patients achieve a pathologically complete response 
(pCR). Both patients that achieve a pCR and patients that 
harbor subclinical disseminated disease after nCRT could 
benefit from an active surveillance strategy. Summary: 
Esophagectomy is still the cornerstone of treatment in pa-
tients with esophageal cancer. Non-surgical treatment via 
definitive chemoradiotherapy (dCRT) is currently reserved 
only for patients not eligible for esophagectomy. Since sal-
vage esophagectomy after dCRT (50–60 Gy) results in in-
creased complications, morbidity and mortality compared 
to surgery after nCRT (41.4 Gy), the latter seems preferable 
in the setting of active surveillance. Clinical response evalu-
ations can detect substantial (i.e., tumor regression grade 
[TRG] 3–4) tumors after nCRT with a sensitivity of 90%, min-
imizing the risk of development of non-resectable recur-
rences. Current scarce and retrospective literature suggests 
that active surveillance following nCRT might not jeopar-
dize overall survival and postponed surgery could be per-
formed safely. Key Message: Before an active surveillance 
approach could be considered standard treatment, results 
of phase III randomized trials should be awaited.
© 2018 The Author(s)  
Published by S. Karger AG, Basel
Introduction
Organ-sparing treatment has been emerging for sev-
eral malignancies and it avoids loss-of-function of the or-
gan due to surgical resection. Over 2 decades ago, this 
treatment strategy was introduced for head and neck can-
cers, more specifically for laryngeal cancer [1, 2]. Salvage 
surgery after initial organ-preservation was reported with 
acceptable rates of postoperative complications [3]. After 
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promising results in laryngeal cancer, similar strategies 
were reported for prostate- and rectal cancer [4–9]. Dur-
ing the surveillance period, mostly after neoadjuvant 
therapy consisting of chemo- and radiotherapy, frequent 
checks are performed to detect residual- or progression 
of disease. Surgical resection is then reserved only for 
those patients in whom residual disease is proven or high-
ly suspected in the absence of distant metastases. In laryn-
geal-, prostate- and rectal cancer, active surveillance has 
been reported a safe strategy without compromising 
overall survival (OS). 
In esophageal cancer, 29% of patients show a patho-
logically complete response (pCR) after neoadjuvant 
chemoradiotherapy (nCRT) according to the CROSS-
regimen [10]. Literature concerning organ-sparing treat-
ment in esophageal cancer patients with a clinically com-
plete response (cCR) after neoadjuvant therapy is scarce. 
Some studies show an OS comparable to standard esoph-
agectomy [11–13]. The retrospective nature and small 
number of included patients in these studies urge the 
need for further research on this topic. Several challenges 
currently restrict widespread use of organ-sparing strate-
gies in esophageal cancer. This review aims at providing 
an overview of the current treatment options and possible 
opportunities towards an organ-sparing treatment in 
esophageal cancer. 
Surgery and (Neo)Adjuvant Therapy
Esophagectomy is still considered a crucial step in the 
curative treatment of locally advanced esophageal cancer. 
One of the first review articles reporting on the outcome of 
esophageal cancer surgery between 1953 and 1978 report-
ed a mean 5-year survival rate of 12% and a hospital mor-
tality rate of 29% [14, 15]. This 5-year survival rate in-
creased to 20% between 1980 and 1988 with a hospital 
mortality of 13% [16]. Both transthoracic- and transhiatal 
esophagectomy showed similar OS of 20% as reported in a 
meta-analysis [17]. However, a Dutch trial (HIVEX-study) 
randomized 220 patients with adenocarcinoma of the mid-
to-distal esophagus or the gastric cardia involving the dis-
tal esophagus and showed a 5-year OS of 27% for the tran-
shiatal approach and 39% for the transthoracic approach 
with extended en bloc lymphadenectomy [18]. Although 
better patient selection and improvement of perioperative 
care resulted in higher survival rates over the last decades, 
the percentage of patients with tumor-free resection mar-
gins remained an issue. For both approaches, the HIVEX-
trial reported 30% microscopically non-radical resections.
In order to reduce the number of non-radical resec-
tions, neoadjuvant therapies consisting of chemo- and/or 
radiotherapy-regimens have been thoroughly studied. 
The first completed, sufficiently powered, randomized 
controlled trial comparing trimodality treatment to sur-
gery alone was published in 1996 [19]. This study includ-
ed 113 patients with esophageal adenocarcinoma and re-
ported a 3-year survival improvement from 6 to 32% after 
nCRT was added to surgery. Another trial comparing tri-
modality-therapy to surgery alone was the CROSS-trial 
[10, 20]. This Dutch multicenter randomized controlled 
trial included 366 patients with esophageal or junctional 
cancer. After nCRT, 92% of the patients underwent a rad-
ical resection of the esophagus versus 69% in the surgery 
alone group. A pCR was achieved in 29% of the patients 
(23% in adenocarcinoma and 49% in squamous cell car-
cinoma). Importantly, 5-year OS improved from 33 to 
47% after adding nCRT to surgery. No increased postop-
erative complications were found in the patients under-
going nCRT. Since the publication of the CROSS-trial, 
nCRT followed by surgery has been adopted as a standard 
treatment for locally-advanced esophageal cancer in large 
parts of the western world.
Also, (neo)adjuvant chemotherapy has been shown to 
be effective in the treatment of esophageal cancer. 
The OEO2-trial was the largest trial that investigated 
the efficacy of neoadjuvant chemotherapy for esophageal 
cancer [21]. Between 1992 and 1998, 802 patients with lo-
cally advanced squamous cell or adenocarcinoma of the 
esophagus from 42 European centers were randomized 
between preoperative chemotherapy (cisplatin and fluo-
rouracil) followed by surgery versus surgery alone. In the 
preoperative chemotherapy group, both disease-free sur-
vival (DFS) (hazard ratio [HR] 0.75; p = 0.0014) and 
2-year OS (HR 0.79; p = 0.004) were higher. Long-term 
results confirmed the improvement in DFS and OS [22]. 
The MAGIC- and the ACCORD-07-trials confirmed the 
efficacy of perioperative chemotherapy in patients with 
esophageal and gastric cancer [23, 24]. Surprisingly, the 
RTOG-8911 trial, randomizing 440 patients with locally 
advanced squamous cell or adenocarcinoma of the esoph-
agus in the period 1990–1995 between preoperative che-
motherapy followed by surgery and surgery alone, failed 
to show an improvement in 5- and 9-year OS after addi-
tion of preoperative chemotherapy, using cisplatin and 
fluorouracil [25, 26]. 
Both chemotherapy and chemoradiotherapy show a 
statistically significant improvement in OS compared to 
surgery alone. The improvement in OS that was observed 
in the CROSS-trial by adding nCRT to surgery (14%) was 
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comparable to the improvement in the MAGIC- and the 
ACCORD-07-trials (13 and 15% respectively). Chemora-
diotherapy probably shows less morbidity and only mod-
erately decreases quality of life [27–30]. To date, no ran-
domized clinical trials powered on OS comparing chemo-
therapy to nCRT according to the CROSS-regimen have 
been published. Currently, 2 studies are addressing this 
question; the Neo-AEGIS trial and the ESOPEC trial [31, 
32]. 
Twenty-nine percent of patients undergoing nCRT ac-
cording to the CROSS-regimen showed pCR compared 
to 3 and 0% in the MAGIC- and ACCORD-07-trials re-
spectively. Distant progression was seen after neoadju-
vant therapy and surgery in 39% of the patients in the 
CROSS-trial after a median follow-up of 84.1 months and 
in 30% after a median follow-up of 68.4 months in the 
ACCORD-07 trial. This suggests that micrometastases 
are already present in many patients at time of diagnosis. 
Both the high pCR rate after CROSS and frequent devel-
opment of distant metastases after (neo)adjuvant therapy 
followed by surgery imposes the dilemma whether all pa-
tients would eventually benefit from esophagectomy, or 
whether surgery should be reserved only for those pa-
tients in whom residual disease after nCRT has been 
proven or is highly suspected, in the absence of distant 
metastases. In this way, esophagectomy could be post-
poned or even avoided, not only in patients who happen 
to attain biologically complete response after nCRT, but 
also in patients developing distant metastases during ac-
tive surveillance, since distant metastases will heavily de-
termine survival in these patients. 
Definitive Chemoradiotherapy
For patients unveiling unfit for surgery due to frailty 
or serious comorbidities or with an unfavorable location 
(e.g., the cervical esophagus) or stage of the tumor (cT4b), 
definitive chemoradiotherapy is the preferred curative 
standard treatment [33]. Definitive nonsurgical therapy 
mostly consists of concurrent chemoradiotherapy, since 
the RTOG 85-01 study reported superiority of chemora-
diotherapy over radiotherapy alone [34–36]. 
Several trials have been performed to compare surgical 
and nonsurgical therapies in operable patients. Between 
1994 and 2002, Stahl et al. [37] randomized 172 patients 
with locally advanced squamous cell carcinoma between 
nCRT followed by esophagectomy and dCRT. Three-year 
OS was similar in both groups. Although the local pro-
gression-free survival was better in the group undergoing 
esophagectomy (64.3 vs. 40.7%; HR 2.1, p = 0.003), treat-
ment-related mortality was higher (12.8 vs. 3.5%; p = 
0.03). Bedenne et al. [38] randomized 259 patients be-
tween 1993 and 2000 with locally advanced esophageal 
cancer between nCRT followed by esophagectomy and 
dCRT. Although the local recurrence rate after 2 years 
was higher in the patients undergoing dCRT (HR 1.63, 
p = 0.03), mortality in the first 3 months postoperatively 
was higher in the esophagectomy group (HR 1.63, p = 
0.002). These results should be interpreted with caution, 
since 2-year OS after nCRT and surgery was only 33.6% 
in contrast to, for example, 67% in the CROSS-trial. Fur-
thermore, the Bedenne et al. [38] trial excluded 43% of the 
patients not responding to nCRT. Subsequent analysis 
showed similar survival between responders and nonre-
sponders undergoing esophagectomy, which seems hard 
to explain [39]. 
Although patients undergo dCRT mostly because 
they are not eligible for esophagectomy, a subgroup of 
patients become eligible after dCRT and undergo esoph-
agectomy for residual or recurrent disease (so called sal-
vage surgery). Several studies reported higher mortality 
and morbidity rates for surgery after dCRT compared to 
surgery after nCRT or compared to surgery alone [40–
42]. Since 5-year OS was reported 25% in these patients 
undergoing salvage esophagectomy, the higher rates of 
complications, morbidity, and mortality were consid-
ered acceptable. However, the indication for salvage 
esophagectomy should be considered with caution and 
only for a selected group of patients. Furthermore, the 
term “salvage esophagectomy” is sometimes used for 
postponed esophagectomy after nCRT and thus, the def-
inition seems unclear. However, salvage surgery after 
dCRT (50–60 Gy) and postponed surgery after nCRT 
(41.4 Gy) should be considered 2 different entities. Be-
cause postponed surgery after nCRT in the context of 
active surveillance is expected to be necessary in a con-
siderable number of patients and dCRT substantially in-
creases adverse postoperative outcomes, nCRT accord-
ing to the CROSS-regimen (41.4 Gy) seems preferable in 
the setting of active surveillance [43, 44].
Clinical Response Evaluation
Before an active surveillance strategy can be imple-
mented, one should address several challenges. Most im-
portantly, OS should not be jeopardized. In order to pre-
vent the development of non-resectable recurrences, re-
sidual disease should be detected at an early stage. Such 
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clinical response evaluations (CREs), mostly comprising 
endoscopy with biopsies, endoscopic ultrasonography 
(EUS), positron emission tomography with 18F-fluorode-
oxyglucose (PET), CT, and/or MRI should determine 
whether or not a patient is considered a clinically com-
plete responder. Accurate CREs should have the ability to 
detect residual cancer while it is still resectable with a high 
chance of a complete tumor removal (radical resection). 
To justify an active surveillance strategy and to safely 
postpone surgery, the value and accuracy of CREs after 
nCRT should be thoroughly studied. 
Since there are no standard protocols for CREs, studies 
concerning these evaluations come with large heteroge-
neity. For endoscopic biopsies, sensitivity of 30–40% and 
specificity of 100% were reported in 3 prospective studies 
[45–47]. Three prospective studies reported sensitivity 
and specificity for EUS ranging from 95 to 100% and 0 to 
47% respectively [46, 48, 49]. Although PET-CT after 
nCRT is mainly used for the detection of distant interval 
metastases, the value in CREs has also been assessed. Two 
prospective studies reported a sensitivity of 51–60% and 
a specificity of 60–67% [45, 50]. One prospective study 
including 64 patients assessed a combination of any of 
these diagnostic modalities (endoscopic biopsies, PET 
and CT) and reported a sensitivity of 76% and specificity 
82% [45]. The most recent and largest trial assessing a 
combination of diagnostic modalities is the preSANO-
trial [51]. This prospective multicenter trial evaluated the 
accuracy of CREs and aimed to determine the optimal set 
of diagnostic modalities to accurately unveil residual 
esophageal cancer after nCRT. Some 207 patients with 
squamous cell or adenocarcinoma of the esophagus or 
esophagogastric junction were included between 2013 
and 2016. The aim of this study was to assess the correla-
tion between the CRE-results and the tumor regression 
grades (TRGs) in the resection specimen. The primary 
endpoint of the study was the proportion of TRG3–4 tu-
mors (> 10% residual tumor cells) as detected during 
CREs. It is assumed that TRG2 tumors (1–10% residual 
tumor cells) can initially be missed based on the assump-
tion that these tumors will develop into detectable TRG3–
4 residual disease during active surveillance and can be 
resected safely and at the right time. Consequently, false-
ly negative results were reflected by the number of pa-
tients showing TRG3–4 residual disease not detected with 
endoscopic biopsies, EUS with fine-needle aspiration 
(FNA) of suspected lymph nodes and/or PET-CT. 
Six weeks after the completion of nCRT, patients un-
derwent a first CRE (CRE-1) with only endoscopic biop-
sies according to the CROSS-regimen. If CRE-1 turned 
out to be negative, a second CRE (CRE-2) was performed 
12 weeks after the completion of nCRT, consisting of 
PET-CT followed by endoscopic biopsies and EUS with 
FNA of all suspected lymph nodes. Afterwards, all pa-
tients underwent surgery. If no vital tumor cells were 
proven during both response evaluations, patients were 
considered cCR and these results were compared to the 
surgical specimen of the patients. Thirty-one percent of 
patients with TRG3–4 tumors were considered cCR using 
endoscopic biopsies and EUS with FNA of all suspected 
lymph nodes. This drastically improved to 10% after the 
introduction of bite-on-bite biopsies. It is thought that 
with bite-on-bite biopsies, deeper layers of the esophageal 
wall can be reached and thus, these biopsies are theoreti-
cally capable of unveiling buried tumors [52]. Further-
more, 10% of patients showed interval metastases, as de-
tected with PET-CT during CRE-1 and CRE-2. These re-
sults were considered sufficient to proceed with the 
SANO-trial (Surgery as Needed for Oesophageal cancer); 
a phase-3 multicenter randomized controlled trial com-
paring active surveillance with immediate surgery [53].
Active Surveillance in Esophageal Cancer
Although literature on the outcomes of nCRT plus ac-
tive surveillance compared to nCRT followed by immedi-
ate surgery in patients with esophageal cancer is scarce, 
some studies have been published. In 2012, Taketa et al. 
[11] retrospectively reviewed 622 patients after chemora-
diotherapy and surgery. A cCR was defined as no vital 
tumor cells in biopsies and having a physiologic range of 
uptake by PET-CT. Sixty-one patients with a cCR refused 
surgery after nCRT and preoperative staging with endo-
scopic biopsies and PET-CT. These patients showed a 
5-year overall- and recurrence-free survival of 58.1 and 
35.3% respectively. One year later, outcomes between pa-
tients declining immediate surgery and patients who un-
derwent standard trimodality-therapy were compared 
using propensity-score matching and no difference in 
3-year OS was reported (62 vs. 56% respectively; p = 0.28) 
[12]. Thirty-one percent of patients who declined imme-
diate surgery eventually underwent a postponed resec-
tion because of residual disease without distant metasta-
ses and all resections were radical. Castoro et al. [13] ret-
rospectively included 77 patients with cCR after 
neoadjuvant therapy of whom 38 had declined surgery 
and 39 had undergone immediate surgery. After propen-
sity-score matching, no differences were reported in 
5-year OS and DFS. 
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Currently, the Dutch SANO- and the French ESO-
STRATE-trials are comparing active surveillance with 
immediate surgery in patients with squamous cell- or ad-
enocarcinoma of the esophagus showing cCR after nCRT 
according to the CROSS-regimen [53]. In the SANO-tri-
al, cCR is defined as endoscopy with multiple bite-on-bite 
biopsies, EUS with FNA of all suspected lymph nodes and 
PET-CT, all showing no signs of residual disease or dis-
tant metastases twelve weeks after the completion of 
nCRT. After having reached cCR, patients are random-
ized to either active surveillance or immediate resection 
according to a stepped-wedge design, that is, based on 
randomization on institutional level and not on individ-
ual level, since randomization between conservative and 
surgical treatment on individual level often fail due to dis-
appointing inclusion rates [54, 55]. 
Future Perspectives
Safe and careful implementation of an organ-sparing 
approach in esophageal cancer depends on several cor-
nerstones. First of all, CREs need to be further improved 
in order to avoid the risk of developing irresectable re-
sidual disease during active surveillance. For this pur-
pose, it should be analyzed why endoscopic bite-on-bite 
biopsies still show false-negative results. Probably, there 
are 2 main reasons; either the location of the residual tu-
mor was superficial but biopsies were not accurately tar-
geted or the residual tumor was too deep for endoscopic 
biopsies to reach the tumor as already suggested in ear-
lier studies [56, 57]. Sampling of large areas of the esoph-
agus during CREs could overcome the issue of sampling 
errors, for instance, the Endosponge® (Medtronic, Min-
neapolis, MN, USA) and the wide-area transepithelial 
sampling procedure [58, 59]. The latter technique uses a 
minimally invasive brush biopsy technique, which sam-
ples layers as deep as the muscularis mucosae. New bi-
opsy instruments reaching deeper parts of the esopha-
geal wall, like fine-needle biopsies (FNB), could over-
come the issue of residual tumor buried under a 
tumor-free (sub)mucosal layer [57, 60, 61]. FNB is con-
sidered safe and is widely used in the gastrointestinal 
tract. Dynamic contrast-enhanced MRI has shown po-
tential benefit in detection of residual disease after nCRT 
[62]. Although PET-CT does not seem accurate enough 
to determine whether or not a patient should undergo 
surgery early after nCRT due to high false-positive rates 
(mostly because of radiation esophagitis), the value of 
semi-quantitative assessment of residual disease with 
PET-CT could be of value during surveillance and is cur-
rently part of the surveillance strategy in the SANO-trial 
[51]. Furthermore, new biomarkers could possibly un-
veil residual tumors in the peripheral blood [63]. An ex-
ample of such biomarkers is circulating tumor DNA 
(ctDNA) that is shed from necrotizing tumor cells freely 
into the peripheral blood. With the help of next-genera-
tion sequencing and whole exome sequencing, very small 
amounts of DNA containing esophageal cancer-specific 
mutations can be detected and thus, can possibly detect 
residual tumors in early phases and as such act as “liquid 
biopsies” [64, 65]. Even though CREs are considered ac-
curate enough in unveiling residual disease, delayed de-
tection of recurrences could theoretically result in in-
creased distant dissemination rate due to prolonged in 
situ time of the primary tumor. Although previous stud-
ies showed no differences in distant dissemination rate 
between patients undergoing nCRT with and without 
surgery, this must be monitored with caution during ac-
tive surveillance [12, 13]. Secondly, implementation of 
an active surveillance strategy should come with some 
side notes. Although an active surveillance strategy 
would have clear clinical advantages, concerns exist 
about whether the active surveillance strategy is warrant-
ed for all patients with cCR. Such a strategy comes with 
more frequent hospital visits and additional invasive di-
agnostic tests that could result in a psychological burden. 
Furthermore, patients could experience anxiety due to 
the fact that, potentially, the tumor has not been treated 
optimally and postponed surgery could still be necessary. 
These factors could outweigh the advantage of prevent-
ing surgery [66]. Earlier studies reported a discrepancy 
in decision-making between the patients and their doc-
tors which underlines the necessity of shared-decision 
making [67]. A recent study suggested that, in the preop-
erative stage, esophageal cancer patients were willing to 
trade-off an average of 15% 5-year survival to decrease 
the need for esophagectomy from 100 to 35% [68]. Fu-
ture studies should confirm these results in the postop-
erative setting. Furthermore, patient factors should be 
identified that are clearly correlated with a preference for 
either immediate surgery or active surveillance to better 
inform and advice patients in decision-making [69]. 
Conclusion
After nCRT up to one-third of patient shows pCR in 
the resection specimen. This evokes a discussion if active 
surveillance might be appropriate in patients with cCR. 
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Currently, the main challenge is to improve the clinical 
identification of tumor residue. 
The scarce retrospective literature suggests that an or-
gan-sparing approach with active surveillance after nCRT 
might not jeopardize OS and postponed surgery could be 
performed safely. Before an active surveillance approach 
can be considered part of standard treatment in patients 
with esophageal cancer, the results of randomized trials 
such as the ESOSTRATE- and the SANO-trial, should be 
awaited.
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